jubilant lifes’ 2 units inspected by us fda without any observations
Published 7 years ago • 130 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
2:33
zydus life dips over 5% after teva gets us fda approval for asacol hd generic | cnbc tv18
-
0:41
is now a good time to invest in gold etfs? | n18s | cnbc tv18
-
5:12
finstreet | q1fy25 performance review of banking sector | cnbc tv18
-
6:41
key stocks in focus: medi assist, gpt infraprojects, ceigall, zydus lifesciences, hcltech, coforge
-
8:00
focussed on operating efficiency and leverage: awfis space solutions | cnbc tv18
-
2:20
jubilant life signs contracts with top distributors in radiopharma biz
-
2:00
zydus under pressure after teva gets us fda approval for asacol hd generic | cnbc tv18
-
0:51
stocks in focus |august 3, 2022|jubilant pharma: us fda issued 6 observations for jubilant pharmova|
-
6:36
will see good margin growth in q2 from all major it players: sowilo investment managers | cnbc tv18
-
2:25
jubilant foodworks under pressure despite in-line q2fy23 results | chartbusters | cnbc-tv18
-
23:49
us fda issues 6 observation on sun pharma | halftime report | cnbc-tv18
-
1:57
us drug regulator issues six observations to lupin's indore plant
-
9:06
expect net interest margin to be at 4.5% for fy25: csb bank | cnbc tv18
-
16:09
real estate is very important for domestic capital formation: manulife investment management
-
8:13
expect credit growth to be in-line with industry at mid-teens for fy25: city union bank | cnbc tv18
-
1:02
ubs upgrades jubilant foodworks to buy, says firm's growth to be driven by aggressive store addition
-
7:10
investing in active & passive funds: the role of thematic funds in a portfolio | cnbc tv18
-
1:40
pharma companies in focus today
-
1:40
firstsource buzzing in trade as mgmt says it will achieve 11.5-13.5% rev growth in fy25 | cnbc tv18